Inovio Pharmaceuticals (INO) Assets (2010 - 2026)

Inovio Pharmaceuticals has disclosed Assets across 17 years of filings, most recently posting $49.4 million for Q2 2026.

• In Q2 2026, Assets fell 27.62% year-over-year to $49.4 million; the TTM figure through Jun 2026 stood at $49.4 million (down 27.62% YoY), while the FY2025 annual figure was $74.3 million, down 34.35% from the prior year.
• Assets came in at $49.4 million for Q2 2026 at Inovio Pharmaceuticals, down from $49.8 million in the prior quarter.
• In the past five years, Assets ranged from a high of $459.4 million in Q2 2022 to a low of $49.4 million in Q2 2026.
• Average Assets over 5 years is $188.4 million, with a median of $131.5 million recorded in 2024.
• Year-over-year, Assets fell 22.38% in 2022 and sank 51.57% in 2024.
• Over 5 years, Assets stood at $348.5 million in 2022, then plunged by 50.95% to $171.0 million in 2023, then sank by 33.78% to $113.2 million in 2024, then sank by 34.35% to $74.3 million in 2025, then slumped by 33.54% to $49.4 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $49.4 million in Q2 2026, $49.8 million in Q1 2026, and $74.3 million in Q4 2025.